



# Financial Tear Sheet

## CORPORATE PROFILE

Delcath Systems, Inc. (OTCQB-DCTH) Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM), and plans to initiate a global registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

## PRIMARY IR CONTACT

Delcath Investor Relations

**E-mail:**

[investorrelations@delcath.com](mailto:investorrelations@delcath.com)

## STOCK PERFORMANCE

### DCTH (Common Stock)

|                    |                       |
|--------------------|-----------------------|
| Exchange           | OTCQB (US Dollar)     |
| Price              | <b>\$2.56</b>         |
| Change (%)         | <b>▼ 0.19 (6.91%)</b> |
| Volume             | 3,046                 |
| 52 Week Low        | \$1.22                |
| Market Cap         | \$2,386,353           |
| Rolling EPS        | -193.40               |
| PE Ratio           | N/A                   |
| Shares Outstanding | 932,169               |

Data as of 06/22/18 11:57 a.m. ET

■ DELCATH SYS INC  
as of 6/21/2018



EDGAROnline

## RECENT HEADLINES & EVENTS

05/29/18

Delcath Systems to Present at the 8th Annual LD Micro Invitational

05/22/18

Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event

05/16/18


Delcath's CHEMOSAT Included in German Treatment

There are currently no events scheduled.



## ANALYST ESTIMATES / RATINGS

Mean Recommendation: **2.0**



Unable to fulfill request.

## SEC FILINGS

| Filing Date | Form |
|-------------|------|
| 06/12/18    | S-1  |
| 06/12/18    | RW   |
| 06/08/18    | 8-K  |
| 05/10/18    | 10-Q |

## CORPORATE GOVERNANCE

|   |  |
|---|--|
| Jennifer Simpson, PhD.,<br>M.S.N., C.R.N.P. | President and Chief Executive<br>Officer                             |
| John Purpura                                | Executive Vice President<br>Regulatory Affairs, Quality<br>Assurance |
| Barbra C. Keck                              | Chief Financial Officer  |

## OWNERSHIP SUMMARY

### Shareholders

|             | Holders | Value (\$MM) | % O/S | Shares  |
|-------------|---------|--------------|-------|---------|
| Institution | 9       | 1.36         | 9.1   | 81,432  |
| Mutual Fund | 0       | .00          | 0.0   | 0       |
| Insider *   | 3       | 373.66       | 11.3  | 101,193 |

\*Insider values reflect direct beneficial ownership.

### Top Holders

|                                  | Shares Held | % O/S | Share Change | Filing Date |
|----------------------------------|-------------|-------|--------------|-------------|
| Ayrton Capital LLC               | 61,720      | 6.9   | 61,482       | 02/13/18    |
| Hudson Bay Capital Management LP | 19,656      | 2.2   | 19,656       | 12/31/17    |
| West Oak Capital, LLC            | 50          | 0.0   | 50           | 03/31/18    |
| Purpura (John)                   | 1           | 0.0   | 1            | 06/06/18    |
| Simpson (Jennifer K)             | 1           | 0.0   | 1            | 06/06/18    |
| Keck (Barbra C)                  | 1           | 0.0   | 1            | 06/06/18    |
| Taglietti (Marco)                | 1           | 0.0   | 1            | 06/06/18    |
| Rueckert (William Dodge)         | 1           | 0.0   | 1            | 06/06/18    |
| Stoll (Roger G)                  | 1           | 0.0   | 1            | 06/06/18    |

Powered by **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed